Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Laboratory DNA analysis procedures patented by Johns Hopkins University were well known in the industry and are therefore invalid, Myriad Genetics said in four patent board filings ( Myriad Genetics, Inc. vs. Kinzler Vogelstein , P.T.A.B., No. IPR2017-01102, petition filed 3/16/17 ; Myriad Genetics, Inc. v. Kinzler Vogelstein , P.T.A.B., No. IPR2017-01105, petition filed 3/16/17 ; Myriad Genetics, Inc. v. Kinzler Vogelstein , P.T.A.B., No. IPR2017-01106, petition filed 3/17/17 ; Myriad Genetics, Inc. v. Kinzler Vogelstein , P.T.A.B., No. IPR2017-01107, petition filed 3/17/17 ).
Myriad told the Patent and Trademark Office’s Patent Trial and Appeal Board March 16 and 17 that four JHU patents, which are exclusively licensed by Esoterix Genetic Laboratories,, part of the Laboratory Corporation of America (LabCorp), are invalid as obvious or anticipated because of prior research publications. Esoterix is suing Myriad for patent infringement in the U.S. District Court for the Middle District of North Carolina, alleging that Myriad’s MyRisk Hereditary Cancer Test infringes the JHU patents that Esoterix licenses.
In February, Myriad reported second-quarter global revenues of $144 million for its MyRisk test. If the patent board determines that the four JHU patents are invalid, it could shake the foundations of Esoterix’s infringement suit against Myriad.
Myriad filed four petitions for inter partes review (IPR) with the PTAB. The IPR is a process created by the America Invents Act to allow third-party challenges of the validity of existing patents due to their lacking novelty by being anticipated under 35 U.S.C. § 102 and/or by being obvious under 35 U.S.C. § 103. If the PTAB grants Myriad’s petition, the challenge will go to trial unless the parties reach a settlement. Bloomberg BNA research has indicated that once an IPR petition is granted, patent owners will often settle with the challenger rather than go to trial.
In its four petitions, Myriad noted the claims it is challenging in the four JHU patents—U.S. Patent Nos. 6,440,706; 7,824,889; 7,915,015; and 8,859,206—recite a method that the JHU calls “digital PCR (polymerase chain reaction).” According to Myriad, digital PCR is a method for distributing a DNA sample into compartments so that each compartment contains, ideally, one or zero molecules of DNA from the sample, carrying out PCR in each compartment, and then analyzing the resulting amplified DNA molecules to determine how many compartments contain each different template DNA molecule.
“The steps comprising what the Patent Owner calls ‘digital PCR’ were well known in the art before the earliest possible priority date for the '889 patent,” Myriad wrote. “In the prior art, this method was often called ‘limiting dilution analysis’ or ‘limiting dilution PCR’ (LDPCR) because the sample is diluted down to the point at which some compartments will be ‘positive,’ i.e., contain a PCR-amplified product, and some will be ‘negative,’ i.e., contain no PCR-amplified product.”
Myriad added, “Patent Owner did nothing more than add a snappy name to the prior art method of LDPCR.”
According to Myriad, by 1994, Kary Mullis, the Nobel Prize-winning inventor of PCR, had edited a book on PCR that included a chapter on quantitative PCR, the use of PCR to quantitate amounts of nucleic acids in a sample. The Mullis chapter discloses and discusses the work of multiple groups of scientists at the time who were carrying out and publishing work involving LDPCR. The earliest priority date for any of the JHU patents is 1999, Myriad said. The petition also asserted that the contested claims were rendered obvious or anticipated by four prior research studies.
In 2015, Myriad sued LabCorp and other companies for infringement of its breast and ovarian cancer composition and method patents and later settled the claims ( 09 LSLR, 2/6/15 ).
Pattie Kushner, LabCorp’s vice president of global corporate communications, told Bloomberg BNA in a March 20 email, “When we first filed the lawsuit, we did so to hold Myriad accountable for infringing on, and to protect, our intellectual property. Beyond that, we will not comment further on the pending litigation and related proceedings.”
The petitions were filed by Quinn Emanuel Urquhart & Sullivan, New York.
To contact the reporter on this story: John T. Aquino in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)